Future Neurology,
Journal Year:
2024,
Volume and Issue:
19(1)
Published: March 20, 2024
Alzheimer's
disease
(AD)
is
considered
a
continuum,
progressing
from
preclinical
to
mild
cognitive
impairment
(MCI)
as
an
early
stage,
before
reaching
clinically
apparent
dementia.
Although
it
difficult
assess
the
potential
impairments
in
performance
of
patients
with
MCI
due
AD,
this
condition
should
be
diagnosed
possible
so
that,
by
means
interventions,
can
maintain
their
quality
life
longer.
Healthcare
systems
support
primary
care
physicians
effort
identify
AD
and
refer
memory
clinics
specialists
who
provide
reliable
diagnosis
initiate
appropriate
management.
This
review
discusses
benefits
earlier
diagnosis,
along
challenges
future
directions.
BioDrugs,
Journal Year:
2023,
Volume and Issue:
38(1), P. 5 - 22
Published: Nov. 13, 2023
Two
monoclonal
antibodies
(mAbs),
aducanumab
and
lecanemab,
have
received
accelerated
approval
from
the
US
FDA
for
initiation
of
treatment
in
early
Alzheimer's
disease
patients
who
proven
β-amyloid
pathology
(Aβ).
One
these,
has
subsequently
full
other
are
poised
positive
review
approval.
Anti-amyloid
mAbs
share
feature
producing
a
marked
reduction
total
brain
Aβ
revealed
by
amyloid
positron
emission
tomography.
Trials
associated
with
slowing
cognitive
decline
achieved
measurable
plaque
range
15–25
centiloids;
trials
agents
that
did
not
reach
this
threshold
were
benefit.
differences
terms
titration
schedules,
MRI
monitoring
schedules
amyloid-related
imaging
abnormalities
(ARIA),
continuing
versus
interrupted
therapy.
The
approximate
30%
observed
is
clinically
meaningful
extended
integrity
delay
onset
more
severe
dementia
phases
disease.
Approval
these
initiates
new
era
therapeutics
disease-modifying
properties.
Further
advances
needed,
i.e.
greater
efficacy,
improved
safety,
enhanced
convenience,
better
understanding
ill-understood
observations
such
as
volume
loss.
JAMA,
Journal Year:
2023,
Volume and Issue:
330(6), P. 507 - 507
Published: July 17, 2023
Our
website
uses
cookies
to
enhance
your
experience.
By
continuing
use
our
site,
or
clicking
"Continue,"
you
are
agreeing
Cookie
Policy
|
Continue
JAMA
HomeNew
OnlineCurrent
IssueFor
Authors
Journals
Network
Open
Cardiology
Dermatology
Health
Forum
Internal
Medicine
Neurology
Oncology
Ophthalmology
Otolaryngology–Head
&
Neck
Surgery
Pediatrics
Psychiatry
Archives
of
(1919-1959)
Podcasts
Clinical
Reviews
Editors'
Summary
Medical
News
Author
Interviews
More
JN
Learning
/
CMESubscribeJobsInstitutions
LibrariansReprints
Permissions
Terms
Use
Privacy
Accessibility
Statement
2023
American
Association.
All
Rights
Reserved
Search
Archive
Input
Term
Sign
In
Individual
inCreate
an
Account
Access
through
institution
Purchase
Options:
Buy
this
article
Rent
Subscribe
the
journal
Alzheimer s & Dementia,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 8, 2025
Abstract
INTRODUCTION
The
Alzheimer's
Association
and
the
Society
of
Nuclear
Medicine
Molecular
Imaging
convened
a
multidisciplinary
workgroup
to
update
appropriate
use
criteria
(AUC)
for
amyloid
positron
emission
tomography
(PET)
develop
AUC
tau
PET.
METHODS
identified
key
research
questions
that
guided
systematic
literature
review
on
clinical
amyloid/tau
Building
this
review,
developed
17
scenarios
in
which
or
PET
may
be
considered.
A
modified
Delphi
approach
was
used
rate
each
scenario
by
consensus
as
“rarely
appropriate,”
“uncertain,”
“appropriate.”
Ratings
were
performed
separately
stand‐alone
modalities.
RESULTS
For
PET,
seven
rated
appropriate,
two
uncertain,
eight
rarely
appropriate.
five
six
DISCUSSION
provide
expert
recommendations
these
technologies
evolving
landscape
diagnostics
therapeutics
disease.
Highlights
updated
goal
is
assist
clinicians
identifying
useful
guiding
diagnosis
management
patients
who
have,
are
at
risk
for,
cognitive
decline
These
intended
dementia
specialists
spend
significant
proportion
their
effort
caring
with
complaints,
well
serve
general
reference
broader
audience
interested
implementation
practice.
Journal of Nuclear Medicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. jnumed.124.268756 - jnumed.124.268756
Published: Jan. 8, 2025
The
Alzheimer's
Association
and
the
Society
of
Nuclear
Medicine
Molecular
Imaging
convened
a
multidisciplinary
workgroup
to
update
appropriate
use
criteria
(AUC)
for
amyloid
positron
emission
tomography
(PET)
develop
AUC
tau
PET.
Methods:
identified
key
research
questions
that
guided
systematic
literature
review
on
clinical
amyloid/tau
Building
this
review,
developed
17
scenarios
in
which
or
PET
may
be
considered.
A
modified
Delphi
approach
was
used
rate
each
scenario
by
consensus
as
"rarely
appropriate,"
"uncertain,"
"appropriate."
Ratings
were
performed
separately
stand-alone
modalities.
Results:
For
PET,
7
rated
appropriate,
2
uncertain,
8
rarely
appropriate.
5
6
Conclusion:
provide
expert
recommendations
these
technologies
evolving
landscape
diagnostics
therapeutics
disease.
Advances in Clinical and Experimental Medicine,
Journal Year:
2023,
Volume and Issue:
32(9), P. 943 - 947
Published: Sept. 7, 2023
On
July
6,
2023,
the
U.S.
Food
and
Drug
Administration
(FDA)
approved
lecanemab
(Leqembi)
for
treatment
of
Alzheimer's
dementia
(AD)
patients.In
2
clinical
trials,
reduced
amyloid
in
brain
slowed
cognitive
decline.Here,
I
review
detail
trial
by
van
Dyck
et
al.
(2023)
entitled
"Lecanemab
early
disease",
published
The
New
England
Journal
Medicine
on
January
5,
2023.In
this
18-month
trial,
did
not
slow
decline
women.This
is
especially
significant
because
women
have
a
twofold
increased
risk
AD
compared
to
men,
that
is,
there
are
times
more
than
men
living
with
AD.Lecanemab
APOE4
carriers;
rather,
it
enhanced
study
participants
genes.This
bad
news
patients,
60-75%
whom
carry
at
least
1
gene.These
negative
results
regarding
lecanemab's
therapeutic
value
make
me
wonder
if
approval
was
worst
decision
FDA
up
till
now,
after
aducanumab
June
7,
2021.
European Journal of Neurology,
Journal Year:
2023,
Volume and Issue:
31(2)
Published: Sept. 11, 2023
Abstract
Our
aim
is
to
review
the
most
recent
evidence
on
novel
antibody
therapies
for
Alzheimer's
disease
directed
against
amyloid‐β.
This
a
joint
statement
of
European
Association
Neurology
and
Psychiatric
Association.
After
numerous
unsuccessful
endeavors
create
disease‐modifying
therapy
disease,
substantial
consistent
supporting
clinical
effectiveness
monoclonal
antibodies
aimed
at
amyloid‐β
finally
emerging.
The
latest
trials
not
only
achieved
their
primary
objective
slowing
progression
over
several
months
but
also
demonstrated
positive
secondary
outcomes
decrease
in
levels
as
observed
through
positron
emission
tomography
scans.
Taken
whole,
these
findings
mark
significant
breakthrough
by
substantiating
that
reducing
yields
tangible
benefits,
beyond
mere
changes
biomarkers.
Concurrently,
regular
utilization
new
generation
drugs
will
determine
whether
statistical
efficacy
translates
into
clinically
meaningful
improvements.
may
well
signify
dawning
era
development
disease.
